Clinical Trial Update: MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial of FT538 for recurrent ovarian, fallopian tube, and primary peritoneal cancer has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• FT538

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Cancer, Solid Tumor | Phase 1 | Status: TERMINATED | Results posted: 2025-08-14